

investors@unidoctor.com | unidoctor.com



Forward Looking Statements

THIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This Presentation does not constitute an offer to sell or a solicitation of offers to buy shares or other securities ("Securities"), assets or products of any company or to invest in any fund and is not intended to form the basis of any investment decision. It is not and shall not be construed as a Private Placement Memorandum, and it is not reviewed or regulated by MiFID, AIFMD, or any other financial authority at this stage.

Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by any company referred to herein or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation, and no reliance, should be placed on such information or opinions. Further, the information in this Presentation is not complete and may change. No company referred to herein nor any of their respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation.

This Presentation is directed only at, and may only be communicated to, (i) persons who are outside the United States within the meaning of Regulation S under the US Securities Act of 1933, as amended (the "US Securities Act") or (ii) inside the United States to persons who are "accredited investors" as defined in Regulation D under the US Securities Act. No public offering of any securities discussed herein is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States and no company is currently intending to register any securities under the US Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulator body of any state or other jurisdiction of the United States, nor any securities regulatory body of any other country or political subdivision thereof, has passed on the accuracy or adequacy of the contents of this Presentation. Any representation to the contrary is unlawful. Persons who do not fall within any of these definitions should not rely on this Presentation or take any action in relation to it. The distribution of this Presentation comes should inform themselves about, and observe, any such restrictions.


Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with any company referred to herein or their representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the relevant company or fund. Recipients of this Presentation should each make their own independent evaluation of the relevance and adequacy of the information in this Presentation and should make such other investigations as they deem necessary. By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. This Presentation may contain forward-looking statements that reflect current expectations regarding future events. Forward-looking statements involve risks and uncertainties, including but not limited to those described under the heading "Risk Factors" in the Company's final prospectus dated December 2, 2021 filed under the Company's SEDAR profile at www.sedar.com. Actual events could differ materially from those projected herein and depend on a number of factors.



Al Powered Health.

The Future of healthcare just got smarter.

By blending artificial intelligence algorithms with state-of-the-art diagnostics, high-speed access, and high-definition communications equipment, eHealth connects doctors, clinicians, and patients and enables them to access high-quality care in innovative new ways.



What is eHealth?

The integration of information and communications technologies (IT) in the health sector.



HOSPITAL CARE: electronic patient admin, laboratory and radiology information; electronic messaging; telemedicine such as teleconsults, telepathology, and teledermatology.



HOME CARE: teleconsults and remote vital signs monitoring systems



PRIMARY CARE: integrates general practitioners and pharmacists for patient management, medical records and electronic prescribing.

Our Solution

Combines Information Technologies with Specialized Diagnostic and Communication Hardware powered by AI for remote consultations designed for easy patient access.



Healthcare is rapidly adopting new technologies So are patients.

Since the onset of COVID-19, The global IoMT* market is projected to grow at a CAGR of 15.9% from \$39.3 billion in 2020 to \$172.4B by 2030¹ and Telemedicine is expected to exceed \$244B by 2032².



^{*}Internet of Medical Things

¹ https://www.precedenceresearch.com/internet-of-medical-things-market - Precedence Research

² https://www.gminsights.com/industry-analysis/telemedicine-market - Global Market Insights

eHealth Market Demand

North American eHealth care is still in its infancy. Following a successful path in Europe, we're preparing to disrupt the system in North America. **Now with the aid of AI, the opportunity has become game-changing.**



Two thirds of patients are ready to upgrade to virtual care, with 8% already having tried it.¹



North America led the industry in 2022 with 53.3% of total revenue.²

FROM

\$102.7B

TO

\$893.7B

The Global eHealth Market is estimated to grow from USD \$102.7B in 2022 to USD \$893.7B by 2032.²

FROM

\$8.03B

TO

\$476.3B

In the US alone eHealth Market was valued at USD 8.30 billion in 2019 and expected to reach USD 476.3B billion by 2032.²

¹ Telehealth Index: 2019 Consumer Survey

² https://www.globenewswire.com/en/news-release/2023/04/24/2652922/0/en/Telehealth-Market-to-Hit-Enormous-Growth-of-24-13-By-2032.html - Precedence Research

Artificial Intelligence Market Demand

Artificial Intelligence in eHealth Care is growing rapidly as features & benefits unlock value



The global artificial intelligence market size was valued at \$428.00 billion in 2022¹



Al in Healthcare grew from \$11.06B in 2021 to \$15.1B in 2022.^{1, 2}



Al can reduce patient wait times and increase identification of false positive results.³

FROM

TO

515.31B

2,025.12B

The global AI Market is estimated to grow from USD \$515.31B in 2023 to USD \$2025.12B in 2030. CAGR 21.6%¹

FROM

TO

15.1B

272.91B

Projected AI in global Healthcare Market is estimated to grow from USD \$15.1B in 2022 to USD \$187.95B by 2030. CAGR 51.8%^{1, 2}

FROM

TO

26 Days

0 Days

The US national average wait time was 21 days in in 2004. In 2022, the wait time had increased to 26 days.³

¹ https://www.fortunebusinessinsights.com/industry-reports/artificial-intelligence-market-100114 - Fortune Business Insights

² https://www.databridgemarketresearch.com/reports/global-artificial-intelligence-in-healthcare-market - Data Bridge Market Research

 $^{3 \} https://www.statnews.com/2023/05/02/doctor-appointment-wait-times-solutions/\#: \sim: text = That \%20 year \%20\%20 the \%20 national \%20 average, an \%20 average \%206\%20 26\%20 days - STAT News of the West-News o$

We believe there is a need for:



LOCATIONS

Easily accessible.



HIGH QUALITY

Experienced physicians.



TIMES

Little to no wait times (pre-book or walk in).



RESULTS

Immediate test results.



SPECIALIST APPOINMENTS

Booked immediately.



SMART DIAGNOSIS

Al Powered Instant Triage & Treatment Plan

This market is ready for powerful disruption.

Our Solution.


UniDoc Virtual eHealth Clinics





UniDoc aims to disrupt the broken elements of North America's healthcare system.

UniDoc goes beyond traditional videocall telemedicine. With a revolutionary new way to interact and collaborate with doctors, UniDoc TriAge Assistant and Virtual Care Model remotely integrates the deductive power of AI powered software systems and a full suite of diagnostic hardware tools and options – the outcome is virtually the same as being in a doctor's office.



Market Opportunity



There are over 68,000 pharmacies in the US.*



There are over 10,000 pharmacies in Canada.**

Proposed locations for Unidoc Virtual eHealth Clinics extends beyond traditional pharmacies:

Grocery Stores

Pharmacies

Long-Term Care Facilities

Post-Secondary Education Campuses

Corporate Offices & More

Underserved and Remote Locations

With easy access, contactless visits and informed results, UniDoc aims to offer improved patient reach and growth opportunities.

*https://www.pcmanet.org/wp-content/uploads/2020/03/FINAL_Independent-Pharmacies-in-the-U.S.-are-More-on-the-Rise-than-on-the-Decline.pdf
**https://www.pharmacists.ca/pharmacy-in-canada/pharmacists-in-canada/#:~:text=Canada%20has%20approximately%2042%2C500%20licensed,%2C%20associations%2C%20colleges%20and%20universities.

Investment Highlights

EFFICIENCY

UniDoc advanced Triage Assistant and Virtual eHealth Clinic Technology aims to provide diagnostic solutions for patients through instant access to high-quality medical care.

TECHNOLOGY

The proprietary technology is tightly integrated with real-time capabilities; An Al algorithm helps inform and advise remote clinicians through a modernized and innovative approach that offers patients real-time diagnoses and testing which we believe is unlike other eHealth technologies on the market.

GLOBAL REACH


Distribution agreements signed for North America, Europe, and Africa.

PARTNERSHIPS

Trusted partnerships with renowned technology and medical organizations, including Hewlett Packard, DocBox Inc., Dedalus Healthcare Systems Group, AMD Global, and Intel.




UniDoc **Virtual Health** Clinics are being designed for intelligent accessible diagnostic capability.



UniDoc Virtual eHealth Clinics aim to:








Provide patients with the convenience and flexibility of having virtual healthcare visits in the comfort of their home or at a point of service close to it.

Allow physicians to expand their practice supported by leading-edge intelligent diagnostic technologies with full access to the patients' clinical data, vital signs and automated triage assessments in real time.

Enable governments, institutions and organizations to set up a low-cost point of service for virtual visits without the financial barriers of in-house physicians' recruitment and retention.

A Complete Solution



KIOSKS AND SELF TEST CENTRES SELF CHECK IN AND TESTING WITH AI POWERED TRIAGE ASSISTANT ACCESS TO DOCTOR AND HOSPITAL NETWORKS







Delivering better patient experiences with devices built to withstand the demands of healthcare environments.



Enabling data-driven healthcare through automating data collection from disparate systems and devices. Our Mission is to be at every ICU bed around the world. Our Vision is to touch 1 billion lives.




For the last 30 years, AMD's integrated medical devices have established a pioneering and leading role in virtual care technology.



Dedalus is a billion-dollar healthcare company with extensive experience in connected care including hospital IT. Dedalus supports over 5000 hospitals and 4800 laboratories worldwide.

With these powerful partnerships, we're positioning for a leading role in the delivery of advanced eHealth solutions.



Leadership



Tony Baldassarre CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multilevel distribution channels.

Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value.

Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.



Franco Staino
Director

Mr. Franco Staino is a business professional with over 40 years experience in the pharmaceutical industry. Mr. Staino has significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italy National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint.

Mr. Staino currently holds multiple positions including being the control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods with high specialization for the pharmaceutical sector, and President of the Board of Directors of Topharmacia, a company that deals with the integral management of pharmacies throughout Italy in order to improve their ability to provide social and commercial services, to connect industrial marketing policy to that of the pharmacy, to offer tools in able to guarantee the financial balance of the companies involved.

Leadership



Dr. Sazzad Hossain, PhD Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian biopharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.



Sina Pirooz
Director

Mr. Pirooz is a registered and practicing pharmacist, and has been a professional member of the College of Pharmacists of British Columbia since 2003, with over 20 years of pharmaceuticals and pharmacy management experience. As owner of a compounding pharmacy, Mr. Pirooz has been dispensing pharmaceuticals for over 18 years and provides pharmacist and pharmacy management services to many of Canada's largest pharmacy chains and drug stores. Mr. Pirooz is also the CEO and a director of Genix Pharmaceuticals Corporation, a company listed for trading on the TSXV.



Austin Thornberry Director

Mr. Thornberry is a seasoned finance professional with a background in advising new companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. Mr. Thornberry has split his time working in Toronto, Ont., and Vancouver, B.C. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.



Matt Chatterton Director

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His expertise includes project management, facility management, logistics, and supply side processes and procedures at a number of operations in Canada and internationally. He has been involved in the public markets for the last three years managing IPO processes and transitioning businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of Canada's Queens University with a Bachelor's degree in Engineering Chemistry (2001) and Master's degree in Chemical Process Engineering (2003).



2024 INVESTOR PRESENTATION

CSE: UDOC | OTCQB: UDOCF

investors@unidoctor.com | unidoctor.com

